TrialCancer prevention research (Philadelphia, Pa.)2011

Bexarotene plus erlotinib suppress lung carcinogenesis independent of KRAS mutations in two clinical trials and transgenic models.

Konstantin H Dragnev et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.